GB9918962D0 - Chemical compounds xxii - Google Patents

Chemical compounds xxii

Info

Publication number
GB9918962D0
GB9918962D0 GBGB9918962.3A GB9918962A GB9918962D0 GB 9918962 D0 GB9918962 D0 GB 9918962D0 GB 9918962 A GB9918962 A GB 9918962A GB 9918962 D0 GB9918962 D0 GB 9918962D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds xxii
xxii
chemical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9918962.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Cerebrus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerebrus Ltd filed Critical Cerebrus Ltd
Priority to GBGB9918962.3A priority Critical patent/GB9918962D0/en
Publication of GB9918962D0 publication Critical patent/GB9918962D0/en
Priority to JP2001517501A priority patent/JP2003507367A/ja
Priority to TR2002/00352T priority patent/TR200200352T2/xx
Priority to MXPA01013235A priority patent/MXPA01013235A/es
Priority to PT00951697T priority patent/PT1202965E/pt
Priority to CA002377646A priority patent/CA2377646A1/en
Priority to ES00951697T priority patent/ES2228588T3/es
Priority to AU64555/00A priority patent/AU773337B2/en
Priority to DK00951697T priority patent/DK1202965T3/da
Priority to US10/009,568 priority patent/US6706750B1/en
Priority to PCT/GB2000/003011 priority patent/WO2001012603A1/en
Priority to DE60014918T priority patent/DE60014918T2/de
Priority to EP00951697A priority patent/EP1202965B1/en
Priority to KR1020027001108A priority patent/KR100740172B1/ko
Priority to AT00951697T priority patent/ATE279392T1/de
Priority to CNB00811515XA priority patent/CN1187330C/zh
Priority to BR0013307-8A priority patent/BR0013307A/pt
Priority to PE2000000807A priority patent/PE20010574A1/es
Priority to ARP000104120A priority patent/AR037222A1/es
Priority to UY26291A priority patent/UY26291A1/es
Priority to ZA200110217A priority patent/ZA200110217B/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
GBGB9918962.3A 1999-08-11 1999-08-11 Chemical compounds xxii Ceased GB9918962D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB9918962.3A GB9918962D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxii
BR0013307-8A BR0013307A (pt) 1999-08-11 2000-08-04 Compostos quìmicos de indol, seus usos e métodos de preparação, método de tratamento, composição e método de fabricação de uma composição farmacêutica que os contêm
PCT/GB2000/003011 WO2001012603A1 (en) 1999-08-11 2000-08-04 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application
EP00951697A EP1202965B1 (en) 1999-08-11 2000-08-04 Indole derivatives, processes for their preparation, pharmaceutical compositions containing them and their medicinal application
MXPA01013235A MXPA01013235A (es) 1999-08-11 2000-08-04 Derivados del indol, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en la medicina.
PT00951697T PT1202965E (pt) 1999-08-11 2000-08-04 Derivados de indol processos para a sua preparacao composicoes farmaceuticas que os contem e a sua aplicacao
CA002377646A CA2377646A1 (en) 1999-08-11 2000-08-04 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application
ES00951697T ES2228588T3 (es) 1999-08-11 2000-08-04 Derivados de indol, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en medicina.
AU64555/00A AU773337B2 (en) 1999-08-11 2000-08-04 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application
DK00951697T DK1202965T3 (da) 1999-08-11 2000-08-04 Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
US10/009,568 US6706750B1 (en) 1999-08-11 2000-08-04 Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal application
JP2001517501A JP2003507367A (ja) 1999-08-11 2000-08-04 インドール誘導体、その調製プロセス、インドール誘導体を含有する薬学的組成物およびその医薬適用
DE60014918T DE60014918T2 (de) 1999-08-11 2000-08-04 Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
TR2002/00352T TR200200352T2 (enExample) 1999-08-11 2000-08-04
KR1020027001108A KR100740172B1 (ko) 1999-08-11 2000-08-04 인돌 유도체들, 이들의 제조 공정, 이들을 함유한약제학적 조성물들 및 그 조성물들의 의약적 적용
AT00951697T ATE279392T1 (de) 1999-08-11 2000-08-04 Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
CNB00811515XA CN1187330C (zh) 1999-08-11 2000-08-04 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
PE2000000807A PE20010574A1 (es) 1999-08-11 2000-08-09 Derivados de indol como ligandos del receptor 5-ht2
ARP000104120A AR037222A1 (es) 1999-08-11 2000-08-10 Un derivado de indol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y un procedimiento para preparar dicha composicion
UY26291A UY26291A1 (es) 1999-08-11 2000-08-11 Compuestos químicos xxii
ZA200110217A ZA200110217B (en) 1999-08-11 2001-12-12 Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918962.3A GB9918962D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxii

Publications (1)

Publication Number Publication Date
GB9918962D0 true GB9918962D0 (en) 1999-10-13

Family

ID=10858982

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9918962.3A Ceased GB9918962D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxii

Country Status (21)

Country Link
US (1) US6706750B1 (enExample)
EP (1) EP1202965B1 (enExample)
JP (1) JP2003507367A (enExample)
KR (1) KR100740172B1 (enExample)
CN (1) CN1187330C (enExample)
AR (1) AR037222A1 (enExample)
AT (1) ATE279392T1 (enExample)
AU (1) AU773337B2 (enExample)
BR (1) BR0013307A (enExample)
CA (1) CA2377646A1 (enExample)
DE (1) DE60014918T2 (enExample)
DK (1) DK1202965T3 (enExample)
ES (1) ES2228588T3 (enExample)
GB (1) GB9918962D0 (enExample)
MX (1) MXPA01013235A (enExample)
PE (1) PE20010574A1 (enExample)
PT (1) PT1202965E (enExample)
TR (1) TR200200352T2 (enExample)
UY (1) UY26291A1 (enExample)
WO (1) WO2001012603A1 (enExample)
ZA (1) ZA200110217B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002044152A1 (en) * 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
WO2002048150A2 (en) * 2000-11-02 2002-06-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7087636B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN1960725A (zh) * 2004-03-15 2007-05-09 Ptc医疗公司 用于抑制血管发生的四环咔啉衍生物
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US7601840B2 (en) * 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
CN101119717A (zh) * 2004-11-23 2008-02-06 Ptc医疗公司 用作抑制vegf产生的活性剂的取代酚
EP1817025A2 (en) * 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US20250051276A1 (en) * 2021-12-15 2025-02-13 Delix Therapeutics, Inc. Aryloxy psychoplastogens and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2541211A (en) * 1948-10-15 1951-02-13 Searle & Co Tertiary-aminoalkyl-tetrahydrocarbazoles
US2687414A (en) 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
DE930988C (de) 1953-01-01 1955-07-28 Bayer Ag Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen
US3151120A (en) * 1961-08-15 1964-09-29 Ciba Geigy Corp Thieno [3, 2-b] indole esters and amides
US3133930A (en) * 1961-08-15 1964-05-19 Ciba Geigy Corp Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids
US3329571A (en) * 1961-10-24 1967-07-04 American Home Prod Methods for treating depression
NL284655A (enExample) 1961-10-24
US3142678A (en) * 1962-01-09 1964-07-28 American Home Prod Amino substituted penthienoindoles
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
TW403738B (en) 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
AU5343298A (en) 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives

Also Published As

Publication number Publication date
PE20010574A1 (es) 2001-05-21
DE60014918T2 (de) 2005-10-13
EP1202965A1 (en) 2002-05-08
EP1202965B1 (en) 2004-10-13
ZA200110217B (en) 2002-12-12
KR20020015078A (ko) 2002-02-27
ES2228588T3 (es) 2005-04-16
AU773337B2 (en) 2004-05-20
PT1202965E (pt) 2005-01-31
CA2377646A1 (en) 2001-02-22
DK1202965T3 (da) 2005-02-14
WO2001012603A1 (en) 2001-02-22
CN1187330C (zh) 2005-02-02
JP2003507367A (ja) 2003-02-25
TR200200352T2 (enExample) 2002-06-21
DE60014918D1 (de) 2004-11-18
AR037222A1 (es) 2004-11-03
AU6455500A (en) 2001-03-13
KR100740172B1 (ko) 2007-07-16
US6706750B1 (en) 2004-03-16
ATE279392T1 (de) 2004-10-15
CN1368960A (zh) 2002-09-11
BR0013307A (pt) 2002-05-28
MXPA01013235A (es) 2002-06-04
UY26291A1 (es) 2001-03-16

Similar Documents

Publication Publication Date Title
GB9907658D0 (en) Chemical compounds
GB9902461D0 (en) Chemical compounds
GB9909409D0 (en) Chemical compounds
GB9903861D0 (en) Chemical compounds
GB9914440D0 (en) Chemical compounds
GB9910104D0 (en) Chemical compounds
GB9910110D0 (en) Chemical compounds
GB9900078D0 (en) Chemical compounds
GB9910394D0 (en) Chemical compounds
GB9914015D0 (en) Chemical compounds
GB9914024D0 (en) Chemical compounds
GB9908355D0 (en) Chemical compounds
GB9914022D0 (en) Chemical compounds
GB9910419D0 (en) Chemical compounds
GB9905077D0 (en) Chemical compounds
GB9905463D0 (en) Chemical compounds
GB9912640D0 (en) Chemical compounds
GB9903857D0 (en) Chemical compounds
GB9901844D0 (en) Chemical compounds
GB9910672D0 (en) Chemical compounds
GB9909582D0 (en) Chemical compounds
GB9910421D0 (en) Chemical compounds
GB9904506D0 (en) Chemical compounds
GB9907656D0 (en) Chemical compounds
GB9910674D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)